stockmarketproxy
/
PCVXNasdaq SEC EDGAR

Vaxcyte, Inc.

Biological Products, (No Diagnostic Substances)·SAN CARLOS, CA·FY end 12/31·CIK 1649094
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue——————
Gross Profit——————
Operating Income-$923.7M-$569.5M-$468.0M-$232.3M-$103.7M
Net Income-$766.6M-$463.9M-$402.3M-$223.5M-$100.1M
Operating CF-$655.6M-$452.6M-$296.8M-$170.6M-$121.4M
Capex$13.7M$22.4M$16.1M$5.8M$6.6M
Free Cash Flow-$669.3M-$475.1M-$312.9M-$176.4M-$127.9M
Buybacks——————
Dividends——————
Gross Margin——————
Operating Margin——————
Net Margin——————
FCF Margin——————
R&D / Revenue——————
Effective Tax——————
Debt / Equity——————
Buybacks / FCF——————

Peer comparison

Biological Products, (No Diagnostic Substances) · 5 peers
CEO Pay Ratio
PCVX
48:1
EXEL
81:1
GILD
119:1
BIIB
113:1
IBRX
69:1
CGON
6:1
CEO total comp
PCVX
$14M
EXEL
$33M
GILD
$28M
BIIB
$24M
IBRX
$13M
CGON
$12M
Net Margin
PCVX
—
EXEL
33.7%
GILD
28.9%
BIIB
13.1%
IBRX
-310.2%
CGON
—